RxDoctor Payments Data

Helen Kidka

Family · Sacramento, CANPI 1093581068

Payments from drug & device makers

$1,431in general payments, 2019–2025

Across 72 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$266
  • AbbVie$249
  • Pfizer$219
  • SPR Therapeutics, Inc$193
  • Ardelyx, Inc.$170
  • Scilex Pharmaceuticals Inc.$96
  • plus $238 from 6 others

What the payments were for

  • Food & beverage$1,431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,431 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$161,834
Medicare patients
493
Services billed
1,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide28$61,949
ZtlidoLidocaine90$52,931
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,142$34,053
BelbucaBuprenorphine Hcl47$32,602
Buprenorphine95$23,647
Xtampza ErOxycodone Myristate30$19,556
OxycontinOxycodone Hcl34$17,174
MovantikNaloxegol Oxalate37$14,659
Lidocaine96$9,505
Diclofenac Sodium86$9,374
Celecoxib94$6,197
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen181$5,506
Morphine Sulfate ErMorphine Sulfate169$4,519
Naloxone Hcl93$4,350
Oxycodone Hcl146$3,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$266$61,94928 claims
Scilex Pharmaceuticals Inc.Ztlido$96$52,93190 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$73$52,15877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →